中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (3): 419-422.doi: 10.3969/j.issn.1673-8225.2011.03.010

• 药物控释材料 drug delivery materials • 上一篇    下一篇

更昔洛韦-纤维蛋白胶-羊膜复合物的缓释特性

蔡明铭1，赵  敏2   

  1. 1重庆市第九人民医院眼科，重庆市   400700
    2重庆医科大学附属第一医院眼科，重庆市   400016
  • 收稿日期:2010-07-18 修回日期:2010-09-19 出版日期:2011-01-15 发布日期:2011-01-15
  • 通讯作者: 赵敏，教授，硕士生导师，重庆医科大学附属第一医院眼科，重庆市 400016 minzhao2002@yahoo.com.cn
  • 作者简介:蔡明铭★，女，1982年生，重庆市人，汉族，2008年重庆医科大学毕业，硕士，医师，主要从事角膜及眼表疾病研究。 mm198222@126.com
  • 基金资助:

    重庆市科技攻关项目(csts2008ac0086)，题目：胶联羊膜制品的开发及临床前研究。

Release characteristics of ganciclovir-fibrin glue-amniotic membrane complex

Cai Ming-ming1, Zhao Min2   

  1. 1Department of Ophthalmology, Ninth People’s Hospital of Chongqing, Chongqing   400700, China
    2Department of Ophthalmology, First Affiliated Hospital of Chongqing Medical University, Chongqing   400016, China
  • Received:2010-07-18 Revised:2010-09-19 Online:2011-01-15 Published:2011-01-15
  • Contact: Zhao Min, Professor, Master’s supervisor, Department of Ophthalmology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China minzhao2002@yahoo.com.cn
  • About author:Cai Ming-ming★, Master, Physician, Department of Ophthalmology, Ninth People’s Hospital of Chongqing, Chongqing 400700, China mm198222@126.com
  • Supported by:

    Scientific and Technological Project of Chongqing, No. csts2008ac0086

PDF

615

被引次数

18

摘要：

背景：近年来，纤维蛋白胶作为药物缓释载体的作用日益受到人们的重视。更昔洛韦是一种有效治疗病毒性角膜炎的广谱抗病毒药物。故选择此药物进行胶联羊膜缓释药膜的初步探索。
目的：观察更昔洛韦-纤维蛋白胶-羊膜复合物的缓释特性，探索临床治疗病毒性角膜炎的新方法。
方法：体外实验：将纤维蛋白胶与更昔洛韦混合后与羊膜黏合，制成更昔洛韦-纤维蛋白胶-羊膜复合物，观察更昔洛韦的体外缓释情况。体内实验：新西兰大白兔右眼为实验组在兔眼表作更昔洛韦-纤维蛋白胶-羊膜移植；左眼为对照组滴1 g/L更昔洛韦眼液，每2 h滴100 μL。应用高效液相色谱法测试不同时间点房水中更昔洛韦的质量浓度。
结果与结论：体外释放实验显示，24 h后更昔洛韦的累计释放率为(45.67±5.32)%，48 h后为(63.42±4.68)%，96 h后释放趋于平衡。动物实验表明：实验组房水中更昔洛韦浓度随时间逐渐降低。第1天时，实验组房水药物浓度显著高于对照组(P < 0.01)。第2，3天，实验组房水更昔洛韦质量浓度稍高，与对照组比较差异无显著性意义。第4，5天，实验组房水药物浓度低于对照组(P < 0.05)。结果提示，在体外及体内条件下，更昔洛韦-纤维蛋白胶-羊膜复合物均具有良好的缓释特性，可望成为治疗病毒性角膜炎的新手段。

关键词: 缓释, 纤维蛋白胶, 羊膜, 更昔洛韦, 病毒性角膜炎

Abstract:

BACKGROUND: In recent years, fibrin glue as a drug delivery carrier, has been attracting a growing attention. Ganciclovir is an effective broad-spectrum antiviral drug of viral keratitis. Therefore, we choose this drug in the initial exploration and research of drug delivery-fibrin glue-amniotic membrane.
OBJECTIVE: To study the release characteristics of ganciclovir-fibrin glue-amniotic membrane and to explore a new method for clinical treatment of viral keratitis. 
METHODS: In vitro study: fibrin glue compounded with ganciclovir and amniotic membrane to prepare the ganciclovir-fibrin glue-amniotic membrane complex and the in vitro release characteristics of ganciclovir was studied. In vivo study: ganciclovir-fibrin glue-amniotic membrane complex was transplanted on right eyes of New Zealand rabbits as experimental group, and 1 g/L ganciclovir dropped into left eye, 100 μL was given in 5 eyes every 2 hours as the control. The ganciclovir concentration in the aqueous humors was assayed by high performance liquid chromatography.
RESULTS AND CONCLUSION: In vitro release study revealed that the accumulative release rate of ganciclovir was (45.67±5.32)% 24 hours after incubation and rose to (63.42±4.68)% 48 hours later. The release process went to a balance condition 96 hours later. Animal indicated that the ganciclovir level in aqueous gradually reduced along with time. The drug level was significantly higher for experimental group than control at 1 day (P < 0.05); during 2-3 days, the drug level in aqueous of experimental group was higher than control group without significant differences; the ganciclovir level in aqueous of experimental group was lower than that of control group at 4-5 days (P < 0.05). The ganciclovir-fibrin glue-amniotic membrane complex has a good sustained release property both in vitro and in vivo, it may be a new treatment of viral keratitis.

中图分类号: